For more information, please contact Rachel Cruthirds, Assistant Vice President for Resource Development; Xavier University of Louisiana.
Inventor: Dr. Tarun K. Mandal
Status: US Patent Application no. 11/591,028 (Publication no. 20080099938 A1)
PCT Application no. PCT/US2007/022514
Description: Microencapsulation of water soluble compounds
Abstract: The invention entails a microencapsulation technique that allows for the efficient manufacturing of acid-salt based medications for sustained release. The method employs a water-oil emulsion containing a biodegradable copolymer, in this case PLGA, whose degradation is easily adjusted to set the appropriate release rate. The experimental model, Buprenorphine HC1, has shown a constant long-term release up to 45 days in-vitro when produced using this method.
Applications: This method of microencapsulation is applicable to any acid-salt. It should be utilized for drugs needing to be administered at a constant rate for an extended period of time. This method advantageously provides a predictable and consistent drug delivery regimen, reducing potential adverse reactions due to initial drug bursts. Although the primary acid salt used during the development of this method was Buprenorphine HC1, other acid-salts are expected to show similar results. From the nature of this method, treatments for the following conditions appear especially relevant: chronic pain and addiction.
Advantages: 1) Prevent active compound loss during the microencapsulation of highly water soluble compounds
2) Reduce initial “burst effect” during release
3) Preparation of long acting sustained release formulation
Inventor: Dr. Tarun K. Mandal
Status: US Patent Application no. 11/739,219; PCT Application no. PCT/IB2008/051529
Description: Automated Control Release Multiple Layer Coating
Abstract: This invention is comprised of a computer controlled, dynamic coating system that is connected to a commercially available fluidized bed. The computerized coating system is currently designed to control flow rate, total volume of solution per cycle, pause time, and the number of total cycles, though other features may be added. Once a delivery program is set, manual oversight is unnecessary, allowing for a hands-off production cycle. This process allows for multiple layers to be formed without changing out solutions in the machine, so as to produce a layer on the tablet that is solely drug or solely coating effectively, a feature that is novel and not commercially available for lab scale multi-layer coating today.
Applications: (1) Automated multiple layer coating for controlled release formulation.
(2) Automated multiple layer coating for agriculture industry.
(3) Automated multiple layer coating with two or more incompatible coating materials.
Advantages: This technology will overall decrease the cost of production for fluid bed owners by decreasing the number of inconsistent batches and by making it more time efficient for relevant applications. It will also decrease the need for manual oversight.
This invention is specifically designed for a laboratory scale fluidized bed system and will be most pertinent for research and development applications. It is envisioned feasible for fluid bed manufactures to offer the presented technology as an add-on product that is specifically designed to use with their system. This will give consumers the opportunity to buy this technology as an additional product suiting specific multi-layer coating needs. Manufacturers may also choose to package this technology in conglomeration with their fluid bed system and sell it as a whole. Although this product is designed for pharmaceutical applications, it may also be used in the fields of probiotics, dietary supplements, and for agricultural applications like fertilizers and insecticides.
Inventor: Dr. Tien L. Huang, et al.
Status: US Patent Application no. 60/873,344; (Pub. No. US 2008/0139534 A1) PCT Application no. PCT/US2007/086773 (International Pub. no. 008/070831 A3)
Description: Bisbenzamidines and bisbenzamidoximes for the treatment of Human African Trypanosomiasis
Abstract: Disclosed are bisbenzamidine and bisbenzamidoxime compounds useful for treatment of trypanosomiasis. The compounds disclosed are useful for treating mammals infected with parasitic hemoflagellates, in particular Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.
Applications: Treatment of HAT
Advantages: The drug candidates of the invention are characterized by high efficacy against drug-sensitive and drug-resistant strains of trypanosoma brucei, low toxicity and good oral bioavailability.
